FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Daniel Coyne

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
Alex J Brown; Daniel W Coyne
Bioavailable vitamin D in chronic kidney disease.
Daniel W Coyne
The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.
Bernard C Camins; Amy M Richmond; Kathrin L Dyer; Heather N Zimmerman; Daniel W Coyne; Marcos Rothstein; Victoria J Fraser
A crossover intervention trial evaluating the efficacy of a chlorhexidine-impregnated sponge in reducing catheter-related bloodstream infections among patients undergoing hemodialysis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Daniel Coyne (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Alex J Brown; Daniel W Coyne
Bioavailable vitamin D in chronic kidney disease.
Kidney international 2012;82(1):5-7.
2012: Daniel W Coyne
The health-related quality of life was not improved by targeting higher hemoglobin in the Normal Hematocrit Trial.
Kidney international 2012;82(2):235-41.
2010: Bernard C Camins; Amy M Richmond; Kathrin L Dyer; Heather N Zimmerman; Daniel W Coyne; Marcos Rothstein; Victoria J Fraser
A crossover intervention trial evaluating the efficacy of a chlorhexidine-impregnated sponge in reducing catheter-related bloodstream infections among patients undergoing hemodialysis.
Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America 2010;31(11):1118-23.
2010: Bradley Ford; Charles S Eby; Mitchell G Scott; Daniel W Coyne
Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients.
Kidney international 2010;78(8):769-73.
2010: Daniel W Coyne; Michael Auerbach
Anemia management in chronic kidney disease: intravenous iron steps forward.
American journal of hematology 2010;85(5):311-2.
2010: Daniel W Coyne
It's time to compare anemia management strategies in hemodialysis.
Clinical journal of the American Society of Nephrology : CJASN 2010;5(4):740-2.
2010: Yekaterina Gincherman; Kirsten Moloney; Charles McKee; Daniel W Coyne
Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients.
Hemodialysis international. International Symposium on Home Hemodialysis 2010;14(1):68-72.
2009: Daniel W Coyne
Ferumoxytol for treatment of iron deficiency anemia in patients with chronic kidney disease.
Expert opinion on pharmacotherapy 2009;10(15):2563-8.
2009: Daniel O Young; Steven C Cheng; James A Delmez; Daniel W Coyne
The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients.
Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis 2009;29(5):562-7.
2009: Daniel W Coyne; Daniel C Brennan
Seeking safe and efficacious anemia management.
Seminars in dialysis 2009;22(5):590-1.
2009: Sijie Zheng; Daniel W Coyne; Heidi Joist; Rebecca Schuessler; Ambyr Godboldo-Brooks; Patrick Ercole; Daniel C Brennan
Iron deficiency anemia and iron losses after renal transplantation.
Transplant international : official journal of the European Society for Organ Transplantation 2009;22(4):434-40.
2009: Daniel W Coyne
Managing anemia in for-profit dialysis chains: when ethics and business conflict.
Seminars in dialysis 2009;22(1):18-21.
2008: Laura T Pizzi; Thomas J Bunz; Daniel W Coyne; David S Goldfarb; Ajay K Singh
Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation.
Kidney international 2008;74(12):1588-95.
2008: Daniel W Coyne; Andrea Sims; Brenda Bingel
Results of an anemia management program to reduce high epoetin doses by targeted use of i.v. ferric gluconate.
Nephrology nursing journal : journal of the American Nephrology Nurses' Association 2008;35(6):583-7.
2008: Steven C Cheng; Daniel O Young; Yihung Huang; James A Delmez; Daniel W Coyne
A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients.
Clinical journal of the American Society of Nephrology : CJASN 2008;3(4):1131-8.
2008: Daniel W Coyne
From anemia trials to clinical practice: understanding the risks and benefits when setting goals for therapy.
Seminars in dialysis 2008;21(3):212-6.
2008: Toros Kapoian; Neeta B O'Mara; Ajay K Singh; John Moran; Adel R Rizkala; Robert Geronemus; Robert C Kopelman; Naomi V Dahl; Daniel W Coyne
Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin.
Journal of the American Society of Nephrology : JASN 2008;19(2):372-9.
2008: Dennis L Andress; Daniel W Coyne; Kamyar Kalantar-Zadeh; Mark E Molitch; Farhad Zangeneh; Stuart M Sprague
Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2008;14(1):18-27.
2008: Bruce Spinowitz; Daniel W Coyne; Charmaine E Lok; Mario Fraticelli; Maher Azer; Sanjay Dalal; Giuseppe Villa; Steven Rosansky; Helena Adamis; Ulrich Beyer
C.E.R.A. maintains stable control of hemoglobin in patients with chronic kidney disease on dialysis when administered once every two weeks.
American journal of nephrology 2008;28(2):280-9.
2007: Ajay K Singh; Daniel W Coyne; W Shapiro; Adel R Rizkala
Predictors of the response to treatment in anemic hemodialysis patients with high serum ferritin and low transferrin saturation.
Kidney international 2007;71(11):1163-71.
2007: Daniel W Coyne; Toros Kapoian; Wadi Suki; Ajay K Singh; John E Moran; Naomi V Dahl; Adel R Rizkala
Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Journal of the American Society of Nephrology : JASN 2007;18(3):975-84.
2007: Sijie Zheng; Vijay Nath; Daniel W Coyne
ACE inhibitor-based, directly observed therapy for hypertension in hemodialysis patients.
American journal of nephrology 2007;27(5):522-9.
2007: Georges Saab; Daniel O Young; Yekaterina Gincherman; Karla Giles; Kathy Norwood; Daniel W Coyne
Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients.
Nephron. Clinical practice 2007;105(3):c132-8.
2006: Steven Cheng; Daniel W Coyne
Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease.
Therapeutics and clinical risk management 2006;2(3):297-301.
2006: H E Joist; Shubhada N Ahya; Karla Giles; Kathy Norwood; Eduardo Slatopolsky; Daniel W Coyne
Differential effects of very high doses of doxercalciferol and paricalcitol on serum phosphorus in hemodialysis patients.
Clinical nephrology 2006;65(5):335-41.
2006: Beckie Michael; Steven Fishbane; Daniel W Coyne; Rajiv Agarwal; David G Warnock
Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex.
Nature clinical practice. Nephrology 2006;2(2):92-100.
2006: Daniel W Coyne; Muralidhar Acharya; Ping Qiu; Hanna Abboud; Daniel Batlle; Steven Rosansky; Stephen Z Fadem; Barton Levine; Laura Williams; Dennis L Andress; Stuart M Sprague
Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2006;47(2):263-76.
2006: Hanna Abboud; Daniel W Coyne; Olgierd Smolenski; Michael Anger; Norman Lunde; Ping Qiu; Richard L Hippensteel; Rajendra S Pradhan; Rameshraja Palaparthy; Anne Kavanaugh; Joel Melnick; Laura A Williams; Daniel Batlle
A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.
American journal of nephrology 2006;26(1):105-14.
2006: Alex J Brown; Matthew J Koch; Daniel W Coyne
Oral feeding acutely down-regulates serum PTH in hemodialysis patients.
Nephron. Clinical practice 2006;103(3):c106-13.
2006: Heidi Joist; Daniel C Brennan; Daniel W Coyne
Anemia in the kidney-transplant patient.
Advances in chronic kidney disease 2006;13(1):4-10.
2005: M E Staniforth; S C Cheng; Daniel W Coyne
Once-weekly intravenous paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients.
Clinical nephrology 2005;63(6):454-60.
2004: Beckie Michael; Daniel W Coyne; Vaughn W Folkert; Naomi V Dahl; David G Warnock
Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2004;19(6):1576-80.
2004: Sharina S Belani; Anne C Goldberg; Daniel W Coyne
Ability of non-high-density lipoprotein cholesterol and calculated intermediate-density lipoprotein to identify nontraditional lipoprotein subclass risk factors in dialysis patients.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2004;43(2):320-9.
2003: Rajiv Agarwal; Allen R Nissenson; Daniel Batlle; Daniel W Coyne; J Richard Trout; David G Warnock
Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States.
The American journal of medicine 2003;115(4):291-7.
2003: Vaughn W Folkert; Beckie Michael; Rajiv Agarwal; Daniel W Coyne; Naomi V Dahl; Pamela Myirski; David G Warnock
Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2003;41(3):651-7.
2003: Daniel W Coyne; N FRANKLIN ADKINSON; Allen R Nissenson; Steven Fishbane; Rajiv Agarwal; Joseph W Eschbach; Beckie Michael; Vaughn W Folkert; Daniel Batlle; J Richard Trout; Naomi V Dahl; Pamela Myirski; Jur Strobos; David G Warnock
Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.
Kidney international 2003;63(1):217-24.
2002: Daniel W Coyne; Marvin Grieff; Shubhada N Ahya; Karla Giles; Kathy Norwood; Eduardo Slatopolsky
Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients.
American journal of kidney diseases : the official journal of the National Kidney Foundation 2002;40(6):1283-8.
2002: Beckie Michael; Daniel W Coyne; Steven Fishbane; Vaughn W Folkert; Robert Lynn; Allen R Nissenson; Rajiv Agarwal; Joseph W Eschbach; Stephen Z Fadem; J Richard Trout; Jur Strobos; David G Warnock
Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
Kidney international 2002;61(5):1830-9.